Exclusive Online Content
BioStem Technologies to Acquire Majority of Assets of Auxocell Laboratories, Inc.
BioStem Technologies Inc. recently announced it has entered into an agreement to acquire the majority of the assets of Auxocell Laboratories, Inc., a leading solid tissue processing equipment manufacturer…..
TCR² Therapeutics & Adaptimmune Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
TCR² Therapeutics Inc. and Adaptimmune Therapeutics recently announced entry into a definitive agreement under which Adaptimmune will combine with TCR² in an all-stock transaction to create a preeminent cell therapy company….
New Data Show CNM-Au8 Preserved ALS Patient Function & Slowed Disease Progression in the Open-Label Extension of the Phase 2 RESCUE-ALS Trial
Clene Inc. and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, recently announced new results showing preserved ALS….
Choosing the Best Drug Stability Solution for a Parental Product
The development of an injectable drug product always comes with the question of the best approach to retaining the product’s stability. We asked Dr. David Brett, Product and Service Manager at Vetter, what must be considered to deal with the….
Checkpoint Therapeutics Announces FDA Filing Acceptance of BLA for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
Checkpoint Therapeutics, Inc. recently announced the US FDA has accepted for filing the Biologics License Application (BLA) for cosibelimab, Checkpoint’s investigational anti-PD-L1 antibody….
SiSaf & the University of Leipzig Partner to Develop Bio-Courier Targeted miRNA for the Treatment of Pancreatic Cancer
SiSaf Ltd recently announced its collaboration with the University of Leipzig, Germany, to develop Bio-Courier targeted micro interfering RNAs (miRNA) for the treatment of….
Incannex Commences Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain & Function in Rheumatoid Arthritis
Incannex Healthcare Limited recently announced it has commenced a Phase 2 clinical trial to assess the safety and efficacy of its proprietary anti-inflammatory combination drug….
EyePoint & Rallybio Announce Research Collaboration
Rallybio Corporation and EyePoint Pharmaceuticals, Inc recently announced a research collaboration. The partnership will evaluate sustained delivery of Rallybio’s inhibitor of complement component….
PDS Biotech Completes Successful Meeting With FDA for Triple Combination of PDS0101, PDS0301 & a Commercial Immune Checkpoint Inhibitor
Received guidance on registrational path for combination in recurrent/metastatic, immune checkpoint inhibitor refractory head and neck cancer….
Ocean Biomedical Celebrates Discovery of Bispecific Antibodies & Immune Checkpoint Inhibitors That Kill Glioblastoma Cells & Melanoma Cells & Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%
Ocean Biomedical, Inc. celebrates the discovery of bispecific antibodies that target Chitinase 3-like-1 and immune checkpoint inhibitors, killing glioblastoma cells and melanoma cells, and blocking the metastasis of malignant….
Cue Biopharma Enters Strategic Collaboration & Option Agreement With Ono Pharmaceutical
Cue Biopharma, Inc. recently announced a collaboration and option agreement with Ono Pharmaceutical Co., Ltd. for CUE-401, a bispecific protein designed to induce and expand regulatory….
Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase
Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, recently announced the development of a new enzyme for double strand oligonucleotide formation with high….
Processa Pharmaceuticals Announces Prioritization on Development of Next-Generation Chemotherapies
Processa Pharmaceuticals, Inc. reiterates the strategic prioritization of its pipeline of proprietary oncology drugs, defined as Next-Generation Chemotherapies (NGCs). Previous studies with these….
Kadimastem Submits IND Application for its Phase 2a Clinical Trial With AstroRx for the Treatment of ALS
Kadimastem Ltd recently has submitted an Investigational New Drug (IND) application to the US FDA for an approval for a multi-site Phase 2a clinical trial to test its lead neurological….
First Subject Dosed in Small Pharma’s First-in-Human Phase 1 Clinical Trial
Phase 1 study will compare two routes of SPL028 administration; intravenous and intramuscular….
VYNE Therapeutics Announces Positive Results from Phase 1a Single & Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor
VYNE Therapeutics Inc. recently announced positive results from the Phase 1a portion of its Phase 1a/b clinical trial evaluating its novel BET inhibitor, VYN201, for vitiligo…..
BioXcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer
BioXcel Therapeutics, Inc. recently announced full data from its Phase 2a trial of BXCL701, the company’s investigational, oral innate immune activator, in combination with….
Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients With Early Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. recently announced the completion of enrollment in its Phase 1 INTERCEPT-AD trial of ACU193 in patients with early Alzheimer’s disease…..
Quotient Sciences Expands Formulation Development Capabilities to Further Accelerate Drug Development Timelines
Company increases laboratory capacity to meet customer demand for fully integrated drug development capabilities….
Gerresheimer & Corning Announce Joint Venture to Meet Growing Demand for Velocity® Vials, Accelerating the Delivery of Life-Saving Treatments
The partnership will combine Gerresheimer’s extensive glass converting expertise with Corning’s Velocity® Vial technology platform, helping set a new standard for the industry….
